HESTER

Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

31 January 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 524669

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: HESTERBIO

Dear Sir / Madam:

Subject: Outcome of Board Meeting

This is with reference to our letter dated 20 January 2022 intimating the date of the Board Meeting for consideration of the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2021.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the Standalone and Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December 2021, as recommended by Audit Committee.

We attach herewith:
1) The approved standalone and consolidated unaudited financial results and limited review reports.
2) Press Release issued in this regard

We would be publishing the extract of results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 11:15 a.m. (IST) and concluded at 11:44 a.m. (IST)

You are requested to take the above information on your record.

Sincerely
For Hester Biosciences Limited

Vinod Mali

Vinod Mali
Company Secretary &
Compliance Officer

HESTER

Hester Biosciences Limited

Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31 DECEMBER 2021

Amount in INR Million

Sr. No.	Particulars	Quarter Ended			Nine Months Period Ended		Year Ended
		31 December 2021	**30 September 2021**	**31 December 2020**	**31 December 2021**	**31 December 2020**	**31 March 2021**
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from Operations	540.01	565.94	528.18	1,691.00	1,453.19	2,084.77
2	Other Income	12.22	13.22	6.35	35.76	15.28	16.48
3	**Total income**	**552.23**	**579.16**	**534.53**	**1,726.76**	**1,468.47**	**2,101.25**
4	**Expenses**						
	(a) Cost of material consumed	77.64	113.10	53.49	265.66	138.19	241.75
	(b) Purchases of stock-in-trade	113.93	89.21	84.22	268.23	171.78	252.09
	(c) Change in inventories of finished goods, traded goods and work in progress	(50.31)	(58.00)	(34.24)	(75.87)	12.64	40.14
	(d) Employee benefits expense	96.70	98.53	86.38	294.23	236.64	334.50
	(e) Finance cost	3.65	3.53	9.38	10.85	34.75	39.47
	(f) Depreciation and amortisation expense	23.34	23.22	24.36	69.54	71.88	96.33
	(g) Other expenses	149.74	151.75	132.49	433.60	380.16	496.35
	Total expenses	**414.69**	**421.34**	**356.08**	**1,266.24**	**1,046.04**	**1,500.63**
5	**Profit before tax and exceptional items**	**137.54**	**157.82**	**178.45**	**460.52**	**422.43**	**600.61**
6	Exceptional items (refer note 3)	-	-	-	-	-	(52.78)
7	**Profit before tax**	**137.54**	**157.82**	**178.45**	**460.52**	**422.43**	**547.83**
8	**Tax Expense**						
	Current tax	35.33	37.74	46.57	122.89	113.87	163.65
	Deferred tax	(3.37)	2.34	(1.03)	(8.06)	(1.86)	(14.83)
	Total tax expense	**31.96**	**40.08**	**45.54**	**114.83**	**112.01**	**148.82**
9	**Profit after tax**	**105.58**	**117.74**	**132.91**	**345.69**	**310.42**	**399.01**
10	**Other Comprehensive Income**						
	Items that will not be reclassified to Profit or Loss						
	Remesurement Gain/(Loss) on Defined Benefit Plans	(1.10)	(2.94)	0.95	(3.32)	2.85	2.86
	Income tax impact	0.28	0.74	(0.24)	0.84	(0.72)	(0.72)
	Total Other Comprehensive Income	**(0.82)**	**(2.20)**	**0.71**	**(2.48)**	**2.13**	**2.14**
11	**Total Comprehensive Income for the period**	**104.76**	**115.54**	**133.62**	**343.21**	**312.55**	**401.15**
12	Paid-up equity share capital						85.07
13	Other Equity						2,290.74
14	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	12.41	13.84	15.62	40.64	36.49	46.90

HESTER

Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

Notes:

1 The standalone financial results of Hester Biosciences Limited (the "Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 31 January 2022.

2 The Statutory Auditors have carried out limited review of the standalone financial results of the Company for the quarter and nine months period ended 31 December 2021.

3 Exceptional items during the year ended 31 March 2021 include Loss on disposal of Patan Farm aggregating to INR 33.21 million and impairment of interest accrued/ loan to subsidiary aggregating to INR 19.57 million.

4 Following are the details of segment wise revenue, results, segment assets and liabilities:

Amount in INR Million

Particulars	Quarter Ended			Nine Months Period Ended		Year Ended
	31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	31 March 2021
Segment Revenue						
a. Poultry Healthcare	416.50	454.94	414.53	1,311.37	1,072.20	1,558.58
b. Animal Healthcare	123.51	111.00	113.65	379.63	380.99	526.19
Total Revenue from Operations	**540.01**	**565.94**	**528.18**	**1,691.00**	**1,453.19**	**2,084.77**
Segment Results						
a. Poultry Healthcare	134.25	148.74	140.03	413.04	275.63	388.39
b. Animal Healthcare	(1.10)	6.89	41.45	34.25	166.27	201.89
Total Segment Results	**133.15**	**155.63**	**181.48**	**447.29**	**441.90**	**590.28**
a. Finance Costs	3.65	3.53	9.38	10.85	34.75	39.47
b. Other unallocable expenditure/(income) (Net)	(8.04)	(5.72)	(6.35)	(24.08)	(15.28)	2.98
Profit before Tax	**137.54**	**157.82**	**178.45**	**460.52**	**422.43**	**547.83**
Segment Assets						
a. Poultry Healthcare	2,490.59	1,932.76	1,758.82	2,490.59	1,758.82	1,822.53
b. Animal Healthcare	328.68	295.23	287.29	328.68	287.29	325.89
Unallocated Assets	702.26	778.51	819.21	702.26	819.21	671.73
Total	**3,521.53**	**3,006.50**	**2,865.32**	**3,521.53**	**2,865.32**	**2,820.15**
Segment Liabilities						
a. Poultry Healthcare	153.46	135.92	278.89	153.46	278.89	143.65
b. Animal Healthcare	43.74	21.83	42.98	43.74	42.98	39.59
Unallocated Liabilities	690.38	319.56	256.25	690.38	256.25	261.10
Total	**887.58**	**477.31**	**578.11**	**887.58**	**578.11**	**444.34**

For and on behalf of the Board of Directors

Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Ahmedabad
Date: 31 January 2022

HESTER

Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS PERIOD ENDED 31 DECEMBER 2021

Amount in INR Million

Sr. No.	Particulars	Quarter Ended			Nine Months Period Ended		Year Ended
		31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	31 March 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
1	Revenue from Operations	556.89	626.62	568.94	1,785.37	1,501.57	2,143.32
2	Other Income	27.77	14.24	12.71	65.49	22.08	46.84
3	**Total Income**	**584.66**	**640.86**	**581.65**	**1,850.86**	**1,523.65**	**2,190.16**
4	**Expenses**						
	(a) Cost of Materials Consumed	146.06	174.52	136.99	442.47	258.00	386.59
	(b) Purchase of Stock-in-Trade	44.39	23.53	28.14	93.17	57.28	79.67
	(c) Change in inventories of finished goods, traded goods and work in progress	(57.38)	(36.53)	(28.36)	(62.46)	24.27	35.97
	(d) Employee Benefit Expense	106.60	111.17	107.91	330.65	277.78	389.23
	(e) Finance Cost	9.62	7.42	15.23	25.64	51.69	66.04
	(f) Depreciation and Amortisation Expense	51.70	30.51	32.66	114.50	96.84	133.14
	(g) Other Expenses	166.91	178.35	112.49	484.96	395.43	565.28
	Total Expenses	**467.90**	**488.97**	**405.06**	**1,428.93**	**1,161.29**	**1,655.92**
5	**Profit Before Tax and Exceptional Items**	**116.76**	**151.89**	**176.59**	**421.93**	**362.36**	**534.24**
6	Exceptional Items (Refer Note 3)	-	-	-	-	-	(33.21)
	Profit before tax	**116.76**	**151.89**	**176.59**	**421.93**	**362.36**	**501.03**
7	**Tax Expense**						
	Current tax	36.57	39.47	48.35	126.63	117.60	169.47
	Deferred tax	(3.11)	1.14	(0.44)	(9.47)	(1.24)	(15.42)
	Total Tax Expense	**33.46**	**40.61**	**47.91**	**117.16**	**116.36**	**154.05**
8	**Profit After Tax**	**83.30**	**111.28**	**128.68**	**304.77**	**246.00**	**346.98**
9	**Other Comprehensive Income**						
	Items that will not be reclassified to Profit or Loss						
	Remeasurement Gain/(Loss) on Defined Benefit Plans	(1.10)	(2.94)	0.95	(3.32)	2.85	2.86
	Income Tax Impact	0.28	0.74	(0.24)	0.84	(0.72)	(0.72)
	Items that will be reclassified to Profit or Loss						
	Foreign Currency Translation Reserve	(1.15)	2.64	(18.18)	3.84	(0.35)	(17.94)
	Income Tax Impact	-	-	-	-	-	-
	Total Other Comprehensive Income	**(1.97)**	**0.44**	**(17.47)**	**1.36**	**1.78**	**(15.80)**
10	**Total Comprehensive Income for the period (7+8)**	**81.33**	**111.72**	**111.21**	**306.13**	**247.78**	**331.18**
11	**Profit for the period attributable to:**						
	(i) Owners of the Company	84.84	106.23	123.45	315.97	247.42	344.30
	(ii) Non Controlling Interest	(1.54)	5.05	5.24	(11.20)	(1.40)	2.68
12	**Other Comprehensive Income for the peiod attributable to:**						
	(i) Owners of the Company	(1.97)	0.44	(18.54)	1.36	(12.30)	(15.80)
	(ii) Non Controlling Interest	-	-	1.07	-	14.09	-
13	**Total Comprehensive Income for the peiod attributable to:**						
	(i) Owners of the Company	82.87	106.67	104.91	317.33	235.11	328.50
	(ii) Non Controlling Interest	(1.54)	5.05	6.30	(11.20)	12.67	2.68
14	Paid-up equity share capital						85.07
15	Other Equity						2,198.01
16	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	9.79	13.08	15.13	35.83	28.92	40.79

HESTER

Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

Notes:

1 The consolidated financial results of Hester Biosciences Limited (the "Company") and its subsidiaries (together referred as the "Group") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 31 January 2022.

2 The Statutory Auditors have carried out limited review of the consolidated financial results of the Group for the quarter and nine months period ended 31 December 2021.

3 Exceptional items during the year ended 31 March 2021 include loss on disposal of Patan farm aggregating to INR 33.21 million.

4 Following are the details of segment wise revenue, results, segment assets and liabilities:

Amount in INR Million

Particulars	Quarter Ended			Nine Months Period Ended		Year Ended
	31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	31 March 2021
Segment Revenue						
a. Poultry Healthcare	419.17	454.50	395.83	1,321.52	1,037.51	1,564.51
b. Animal Healthcare	137.72	172.12	173.11	463.85	464.06	578.81
Total Income from Operations (Net)	**556.89**	**626.62**	**568.94**	**1,785.37**	**1,501.57**	**2,143.32**
Segment Results						
a. Poultry Healthcare	140.05	145.16	101.02	419.66	220.62	389.11
b. Animal Healthcare	(4.06)	21.88	84.45	22.29	177.71	180.92
Total Segment Results	**135.99**	**167.04**	**185.47**	**441.95**	**398.33**	**570.03**
a. Finance Costs	9.62	3.53	15.23	25.64	51.69	66.04
c. Other unallocable expenditure/ (income) (Net)	9.61	11.62	(6.35)	(5.62)	(15.72)	2.96
Profit before Tax	**116.76**	**151.89**	**176.59**	**421.93**	**362.36**	**501.03**
Segment Assets						
a. Poultry Healthcare	2,564.57	2,014.45	1,925.30	2,564.57	1,925.30	1,891.35
b. Animal Healthcare	2,122.28	1,948.87	2,360.74	2,122.28	2,360.74	1,993.65
Unallocated Assets	263.52	339.77	659.10	263.52	659.10	225.49
Total	**4,950.37**	**4,303.09**	**4,945.14**	**4,950.37**	**4,945.14**	**4,110.49**
Segment Liabilities						
a. Poultry Healthcare	186.60	160.14	240.19	186.60	240.19	220.23
b. Animal Healthcare	446.84	376.85	660.36	446.84	660.36	309.87
Unallocated Liabilities	1,737.57	1,266.92	1,323.08	1,737.57	1,323.08	1,220.81
Total	**2,371.01**	**1,803.91**	**2,223.63**	**2,371.01**	**2,223.63**	**1,750.91**

5 Key numbers of the standalone financial results of the Company for the quarter and 9 months period ended 31 December 2021 are as under:

Amount in INR Million

Particulars	Quarter Ended			Nine Months Period Ended		Year Ended
	31 December 2021	30 September 2021	31 December 2020	31 December 2021	31 December 2020	31 March 2021
Total Income	552.23	579.16	534.53	1,726.76	1,468.47	2,101.25
Profit Before Tax and Exceptional Items	137.54	157.82	178.45	460.52	422.43	600.61
Profit before tax	137.54	157.82	178.45	460.52	422.43	547.83
Profit After Tax	105.58	117.74	132.91	345.69	310.42	399.01
Total Comprehensive Income	104.76	115.54	133.62	343.21	312.55	401.15

The Standalone Financial Results are available at the Company's website www.hester.in and on the website of the stock exchanges www.bseindia.com and www.nseindia.com.

For and on behalf of the Board of Directors

Rajiv Gandhi
CEO & Managing Director
DIN: 00438037

Place: Ahmedabad
Date: 31 January 2022

Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • **(M)** 90330 34430 • **E-mail :** cmshah@cmshah.com • **Website :** www.cmshah.com

Independent Auditor's review report on Quarterly and Year-to-Date Unaudited Standalone Financial Results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Hester Biosciences Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Hester Biosciences Limited** for the quarter ended on December 31, 2021 and year to date results for the period from April 01, 2021 to December 31, 2021, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in accordance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a Report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting principles and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed or that it contains any material misstatement.

For Chandulal M. Shah & Co.
Chartered Accountants
FRN No. 101698W

Arpit D. Shah
Partner
M. No. 135188
UDIN: 22135188AAAAAS7990

Place: Ahmedabad
Date : January 31, 2022

CHANDULAL M SHAH & CO. AHMEDABAD CHARTERED ACCOUNTANTS

Chandulal M. Shah & Co.

CHARTERED ACCOUNTANTS

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.
Tel. : 079-2960 1085 • (M) 90330 34430 • E-mail : cmshah@cmshah.com • Website : www.cmshah.com

Independent Auditor's review report on Quarterly and Year-to-date Unaudited Consolidated financial results of Hester Biosciences Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Hester Biosciences Limited** (the "Holding company") and its subsidiaries (the Holding and its subsidiaries together referred to as the "Group") for the quarter ended on December 31, 2021 and year to date results for the period from April 01, 2021 to December 31, 2021 (the "Statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed u/s 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a Report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The statement includes the results of the following subsidiaries:

Sr. No.	Name of the Company
1	Texas Lifesciences Private Limited
2	Hester Biosciences Nepal Private Limited
3	Hester Biosciences Africa Limited
4	Hester Biosciences Kenya Limited
5	Hester Biosciences Tanzania Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting principles and policies has not disclosed the

CHANDULAL M. SHAH & CO.
AHMEDABAD
CHARTERED ACCOUNTANTS

information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements of 2 subsidiaries which have been reviewed by other auditors, whose interim financial statements reflect total revenue of INR 97.76 million and INR 288.35 million, total net profit / (loss) after tax of INR (5.44) million and INR 2.23 million and total comprehensive income / (loss) of INR (5.44) million and of INR 2.23 million for the quarter ended on December 31, 2021 and for the period from April 01, 2021 to December 31, 2021 respectively, as considered in the consolidated unaudited financial results. The interim financial statements of these subsidiaries have been reviewed by the other auditors whose reports have been furnished to us, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of such other auditors and the procedures performed by us as stated in paragraph 3 above.

7. The consolidated unaudited financial results includes the interim financial statements of 3 subsidiaries which have not been reviewed by their auditors, whose interim financial statements reflect total revenue of INR 18.89 million and INR 50.81 million, total net loss after tax of INR 15.77 million and INR 29.53 million and total comprehensive loss of INR 14.85 million and of INR 27.15 million for the quarter ended on December 31, 2021 and for the period from April 01, 2021 to December 31, 2021 respectively as considered in the consolidated unaudited financial results. The management has certified these financial statements and other financial information.

8. Certain of these subsidiaries are located outside India whose financial results have been prepared in accordance with accounting principles generally accepted in their respective countries ('local GAAP'). The Holding Company's management has converted the financial results of such subsidiaries from local GAAP to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based on the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our conclusion on the statement in respect of the matters stated in paragraph 6, 7 and 8 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial statements and financial information certified by the Management.

For Chandulal M. Shah & Co.
Chartered Accountants
FRN No. 101698W

Arpit D. Shah
Partner
M. No. 135188
UDIN: 22135188AAAAAT3509

Place: Ahmedabad
Date : January 31, 2022

CHANDULAL M. SHAH & CO.
AHMEDABAD
CHARTERED ACCOUNTANTS

HESTER

Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

Press Release

31 January 2022

Hester Biosciences Limited Q3 and 9M FY22 Results

Sales up by 9% and 23% for Q3 and 9M FY22, respectively

Hester Biosciences Limited announced the financial results of Q3 and 9M of FY 2021-22. The company achieved an improved operational and financial performance in the period as compared to the corresponding period last year.

The company is constantly investing in geographical market expansion and manpower to achieve the budgeted top-line along with expanding the existing production capacity, a part of which, will be ready from the next quarter.

Financial Highlights (Standalone)

(INR Million)

Particulars	Q3			9M		
	FY22	FY21	Growth	FY22	FY21	Growth
Revenue from operations	540.01	528.18	2%	1,691.00	1,453.19	16%
Net Profit	105.58	132.91	(21%)	345.69	310.43	11%
EPS (In INR) (not annualised)	12.41	15.62	(21%)	40.64	36.49	11%

- Domestic sales have registered a growth of 3% in Q3 FY22, and 24% in 9M FY22.
- Exports have increased by 88% in Q3 FY22 and 14% in 9M FY22.
- Overall, the sales grew by 2% in Q3 FY22, and 16% in 9M FY22, as compared to the corresponding period(s).

Division-wise Revenue Contribution

(INR Million)

Particulars	Q3			9M		
	FY22	FY21	Growth	FY22	FY21	Growth
Poultry Healthcare	416.50	396.09	5%	1,274.88	1,037.77	23%
Animal Healthcare	123.51	98.97	25%	379.63	308.27	23%
Product Sales	**540.01**	**495.06**	**9%**	**1,654.51**	**1,346.04**	**23%**
License fees & services	-	33.12	-	36.49	107.15	(66%)
TOTAL	**540.01**	**528.18**	**2%**	**1,691.00**	**1,453.19**	**16%**

- The revenue during the corresponding previous quarter (Q3 FY21) included a one-time license fee and services of INR 33.12 million against which there is no income in the current year. This has an impact of 6% on margins during that period.

HESTER

Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

Product-wise Revenue Contribution

(INR Million)

Particulars	Q3			9M		
	FY22	FY21	Growth	FY22	FY21	Growth
Vaccines	386.29	386.82	0%	1,274.88	1,037.77	16%
Health Products	153.72	108.24	42%	379.63	308.27	49%
Total Sales	**540.01**	**495.06**	**9%**	**1,654.51**	**1,346.04**	**23%**

- Overall, the sales of vaccines have remained the same in Q3 FY22, but have registered a growth of 16% in 9M FY22. Last year around Q2, Q3 and Q4, there were major disease outbreaks in the poultry industry which led to a spurt in the demand for poultry vaccines. While our vaccines kept the poultry industry immunised from the disease in the last financial year, the over-all poultry health situation has been better this year, thereby registering a normal growth.
- The sales of health products have registered a growth of 42% in Q3 FY22 and 49% in 9M FY22.

Profitability Analysis

Particular	Q3FY22	Q3FY21	Up/(Down)	9MFY22	9MFY21	Up/(Down)
Gross Profit Margin	57.62%	68.22%	(10.60%)	59.37%	64.04%	(4.67%)
EBITDA Margin	28.21%	38.97%	(10.77%)	29.87%	35.35%	(5.48%)
Net Profit Margin	19.55%	25.16%	(5.61%)	20.44%	21.36%	(0.92%)

- On the account of COVID restrictions during Q3, there was a reduction in the expenses for traveling and conveyance, which has contributed for better margins in that period.
- There has been an increase in the bottom-line for the period of nine months. This has mainly been the result of focusing on the manufacturing expenses and effective fund management.

Balance Sheet Analysis

Particular	Q3FY22	Q3FY21	Up/(Down)	9MFY22	9MFY21	Up/(Down)
Return on Equity	16.03%	20.18%	(4.15%)	17.50%	18.05%	(0.55%)
Return on Assets	11.99%	15.10%	(3.10%)	13.09%	14.41%	(1.32%)

Subsidiaries Results Analysis

- The manufacturing plant at Hester Africa has started the production of vaccines against PPR and CBPP. This project will enable Hester to become a leading player in Africa and contribute significantly towards the social as well as economic growth of Tanzania and of the African continent, besides adding to the top-line and bottom-line of Hester.
- With the increase in the healthcare business, Texas Lifesciences is showing a constant growth in top-line as well as bottom-line, and we are expecting the same to continue for the rest of the year.
- Hester Nepal has seen a turnaround with the execution of export orders. Further, we are expecting to achieve a higher turnover once the FAO tender for the PPR vaccine worldwide comes through. This is expected to come by the end of Q4FY22.

HESTER

Hester Biosciences Limited
Head Office
Pushpak, 1st Floor
Panchvati Circle
Motilal Hirabhai Road
Ahmedabad 380006
Gujarat, India
Phone +91 79 26445106

Factory
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +91 2764 285 502
+91 2764 285 453

Email mail@hester.in
Toll Free 1 800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

Other developments

1. The development of vaccines against Classical Swine Fever (CSF), Lumpy Skin Disease (LSD) and Sheep Pox is going as per the timeline and the commercial production is expected to start by Q1FY23.
2. The company is all set to launch the modified Inactivated Coryza Vaccine (an advanced version of the conventional Coryza Vaccine from the existing poultry vaccine portfolio) by the end of Q4 FY22.
3. The PPR national tender has been awarded to the company by the Department of Animal Husbandry and Dairying (DAHD) for the eradication of the PPR disease nationally. Under this program, the company will supply the PPR vaccine throughout the country for two years. This will come into implementation by Q4 FY22, giving a significant growth in FY23. The tendered supplies would be for 200 million doses in two years.
4. In order to grow and expand the Animal Healthcare division further, the company is in the process of expanding the existing product portfolio, wherein a range of therapeutic products will be introduced by the end of Q4.
5. The company is in the final stage of launching the pet division, in terms of identifying the geographies and products. The aim is to commercialise the division by the end of Q4 FY22. The company has started the process of recruitment for the pet division.
6. The capacity enhancement projects mentioned earlier are well executed within the declared the timeline:
   1. The increase of the bulk antigen production capacity for animal vaccines, will be completed before the end of Q4FY22.
   2. Creation of the fill-finish line for animal vaccines, will be completed by Q3 FY23.

Status on Hester's initiatives in developing Covid-19 vaccine

- The company, along with Gujarat Biotechnology Research Centre (GBRC), Government of Gujarat (GoG), has entered into a licensing agreement with Bharat Biotech to manufacture the Drug Substance for *Covaxin*.
- The company is currently building the BSL-3 facility suitable for manufacturing the Drug Substance for *Covaxin*. The construction is going to be completed by Q4FY22.
- The project is progressing well as per the timeline to manufacture up to 7 million doses per month, equivalent Drug Substance for Bharat Biotech.
- The impact on the top-line could be up to over a 100% growth, with this project going on-stream.

About Hester Biosciences Limited:

Hester Biosciences Limited is a leading animal healthcare company engaged in manufacturing and marketing of animal vaccines and healthcare products. The company operates with a singular focus of improving the health of animals, monitoring and preventing diseases in them, thereby enabling better health for human beings.

The company is progressing through innovation and building capacities to unlock untapped potential and also aims to play a bigger role in strengthening the livestock industry in India and contributing to the nation's development.

For more information, please visit www.hester.in